Mesalamine To Reduce Immune Activation During HIV Infection: A Randomized Controlled Trial

Trial Profile

Mesalamine To Reduce Immune Activation During HIV Infection: A Randomized Controlled Trial

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2014

At a glance

  • Drugs Mesalazine (Primary)
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Apr 2014 New trial record
    • 06 Mar 2014 Results presented at the 21st Conference on Retroviruses and Opportunistic Infections.
    • 04 Mar 2014 Primary endpoint 'CD8+-cell-percentage' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top